Skip to main content
. 2023 Nov 26;23:296. doi: 10.1186/s12935-023-03154-8

Fig. 4.

Fig. 4

ARID1A-deficient gastric cancer immunotherapy synergistic targeted therapy strategy. ARID1A, the AT-rich interaction domain 1 A; PD-L1, programmed cell death ligand 1; TMB, tumor mutation burden; dMMR, different Mismatch Repair; MSI-H, microsatellite instability-high; TILs, Tumor Infiltrating Lymphocytes; PARP, poly (ADP-ribose) polymerase; EZH2, enhancer of zeste homolog 2; GSH, glutathione